Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer on October 16, 2025 checkpoint inhibitor Co. KEYNOTE-B96 trial Keytruda Merck ovarian neoplasm Overall Survival PD-L1 pembrolizumab platinum-resistant Progression-Free Survival +
Exelixis' Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study on June 24, 2025 atezolizumab checkpoint inhibitor Clinical Trials Colorectal Carcinoma Exelixis Overall Survival STELLAR-303 Stivarga zanzalintinib +